Motus GI last week closed an initial public offering worth $18 million for its Pure-Vu system for intra-colonoscopy cleaning.
Fort Lauderdale-based Motus said it plans to use the proceeds to commercialize Pure-Vu and for R&D, among other things. The company said it sold 3.5 million shares at $5 apiece, grossing $17.5 million, and also granted a 30-day over-allotment of 525,000 shares to its underwriters.
Motus GI originally hoped to raise $28.8 million in the IPO when it announced it in early January. When the company set its terms for the offering, it had a midpoint of nearly $26 million. The stock, which trades on the NASDAQ exchange under the “MOTS” symbol, was trading at $4.34 per share today, up 8.5% in early trading.
The Pure-Vu cleaning system is designed to be used with a standard colonoscope to perform intra-procedural cleaning of poorly prepared colons.
Piper Jaffray was the lone book-runner for the flotation, with Oppenheimer acting as lead manager.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.